

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.,

Petitioner,

v.

SHANGHAI MIRACOGEN INC,

Patent Owner.

Case No. IPR025-00685

Patent No. 10,792,370

PETITIONER'S NOTICE OF SUPPLEMENTAL EVIDENCE

TABLE OF EXHIBITS

Exhibit	Description
EX1001	U.S. Patent No. 10,792,370 to Hu (“the ’370 patent”)
EX1002	Declaration of Stylianos Bournazos, Ph.D.
EX1003	File History of U.S. Patent No. 10,792,370 Part 1
EX1004	File History of U.S. Patent No. 10,792,370 Part 2
EX1005	U.S. Patent Application Publication No. US 2015/071923 (“Wei”)
EX1006	International Publication No. WO 2014/152199 (“Leanna”)
EX1007	Chinese Patent Application Publication No. CN103772504 (“Liu”)
EX1008	Certified English Translation of Chinese Patent Application Publication No. CN103772504 (“Liu”)
EX1009	International Publication No. WO 2015/000062 (“Tikhomirov”)
EX1010	Metrangolo & Engelholm, Cancers (Basel), 16(2):447 (2024)
EX1011	Tsurushita, et al., Methods., 36(1):69-83 (2005)
EX1012	Jorissen, et al., Exp Cell Res., 284(1):31-53 (2003)
EX1013	Olayioye, et al., EMBO J., 19(13):3159-67 (2000)
EX1014	Bou-Assaly & Mukherji, AJNR Am J Neuroradiol., 31(4):626-7 (2010)
EX1015	McCombs & Owen, AAPS J., 17(2):339-51 (2015)
EX1016	Kovtun & Goldmacher, Cancer Lett., 255(2):232-40 (2007)
EX1017	Okeley, et al., Clin Cancer Res., 16(3):888-97 (2010)
EX1018	Nagaria, et al., Neoplasia, 15(8):939-51 (2013)

EX1019	Perez, et al., Drug Discovery Today, 19(7): 869-881 (2014)
EX1020	Alley, et al., Curr Opin Chem Biol., 14(4):529-37 (2010)
EX1021	Younes, et al., Nat Rev Drug Discov., 11(1):19-20 (2012)
EX1022	Hwang & Foote, Methods., 36(1):3-10 (2005)
EX1023	Herbst & Shin, Cancer., 94(5):1593-611 (2002)
EX1024	Martinelli, et al., Clin Exp Immunol., 158(1):1-9 (2009)
EX1025	Atalay, et al., Ann Oncol., 14(9):1346-63 (2003)
EX1026	Doronina, et al., Nat Biotechnol., 21(7):778–784 (2003)
EX1027	Mao, et al., Cancer Res., 64 (3): 781–788 (2004)
EX1028	Afar, et al., Mol Cancer Ther., 3(8):921-32 (2004)
EX1029	Doronina, et al., Bioconjug Chem., 17(1):114-24 (2006)
EX1030	Chinese Patent Application No. 201510085038.8 (“the ’038.8 Provisional”)
EX1031	De Goeij, et al., Mol Cancer Ther., 14(5):1130-40 (2015)
EX1032	U.S. Patent No. 9,493,568 to Reilly, et al.
EX1033	Khan, et al., World J Gastroenterol., 20(11):2979-94 (2014)
EX1034	Foltz, et al., Circulation., 127(22):2222-30 (2013)
EX1035	Certified English Translation of Chinese Patent Application No. 201510085038.8 (“the ’038.8 Provisional”)
EX1036	Supplemental Declaration of Joe Chen, Ph.D., Esq. (NOT FILED)
EX1037	Supplemental Certification of Translation of Chinese Patent Application No. 201510085038.8 (EX1035) (NOT FILED)

EX1038	Supplemental Certification of Translation of Chinese Patent Application Publication No. CN103772504 (EX1008) (NOT FILED)
EX1100	CSPC Pharmaceutical Group Ltd. Voluntary Announcement, “CPO301 Granted the Third Fast Track Designation by U.S. FDA for the Treatment of Adult Patients with NSCLC” (May 19, 2025)
EX1101	CSPC Megalith Biopharmaceutical Co., Ltd, Study of SYS6010 and Platinum-based Chemotherapy in Patients with EGFR-mutated NSCLC. ClinicalTrials.gov Identifier: NCT06927986 (April 15, 2025)
EX1102	CSPC Megalith Biopharmaceutical Co., Ltd, Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors. ClinicalTrials.gov Identifier: NCT06775236 (March 19, 2025)
EX1103	National Cancer Institute, A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors. Cancer.gov.

Petitioner's supplemental evidence is being timely served within ten business days from the date of Patent Owner's objections pursuant to 37 CFR §42.64(b)(2).

PETITIONER'S SUPPLEMENTAL EVIDENCE

Subject to and without waiver of the foregoing responses, the following is a description of Petitioner's supplemental evidence served herein:

1. EX1036 – Supplemental Declaration of Joe Chen, Ph.D., Esq.
2. EX1037 – Supplemental Certification of Translation of Chinese Patent Application No. 201510085038.8 (EX1035)
3. EX1038 - Supplemental Certification of Translation of Chinese Patent Application Publication No. CN103772504 (EX1008)

Dated: November 12, 2025

By: /s/ Joe Chen
Joe G. Chen, Ph.D.
(Reg. No. 70,066)
Fox Rothschild LLP
Counsel for Petitioners

CERTIFICATE OF SERVICE

Pursuant to 37 CFR § 42.6(e), I hereby certify that on November 12, 2025, I caused a true and correct copy of the foregoing Petitioners' Notice of Supplemental Evidence to be served by electronic mail, as authorized by Patent Owner, at the following email addresses:

Lead Counsel

Christopher Ponder (Reg. No. 77,167)
cponder@sheppardmullin.com

Backup Counsel

Alex Nie, Reg. (Reg. No. 60,523)
anie@sheppardmullin.com

Fangzhou Qiu, (Reg. No. 82,810)
fqiu@sheppardmullin.com

Dated: November 12, 2025

By: s/ Joe Chen
Joe G. Chen, Ph.D.
Reg. No. 70,066
Counsel for Petitioners